Cargando…

Leveraging big data to transform target selection and drug discovery

The advances of genomics, sequencing, and high throughput technologies have led to the creation of large volumes of diverse datasets for drug discovery. Analyzing these datasets to better understand disease and discover new drugs is becoming more common. Recent open data initiatives in basic and cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, B, Butte, AJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785018/
https://www.ncbi.nlm.nih.gov/pubmed/26659699
http://dx.doi.org/10.1002/cpt.318
_version_ 1782420342409527296
author Chen, B
Butte, AJ
author_facet Chen, B
Butte, AJ
author_sort Chen, B
collection PubMed
description The advances of genomics, sequencing, and high throughput technologies have led to the creation of large volumes of diverse datasets for drug discovery. Analyzing these datasets to better understand disease and discover new drugs is becoming more common. Recent open data initiatives in basic and clinical research have dramatically increased the types of data available to the public. The past few years have witnessed successful use of big data in many sectors across the whole drug discovery pipeline. In this review, we will highlight the state of the art in leveraging big data to identify new targets, drug indications, and drug response biomarkers in this era of precision medicine.
format Online
Article
Text
id pubmed-4785018
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-47850182016-03-09 Leveraging big data to transform target selection and drug discovery Chen, B Butte, AJ Clin Pharmacol Ther State of the Art The advances of genomics, sequencing, and high throughput technologies have led to the creation of large volumes of diverse datasets for drug discovery. Analyzing these datasets to better understand disease and discover new drugs is becoming more common. Recent open data initiatives in basic and clinical research have dramatically increased the types of data available to the public. The past few years have witnessed successful use of big data in many sectors across the whole drug discovery pipeline. In this review, we will highlight the state of the art in leveraging big data to identify new targets, drug indications, and drug response biomarkers in this era of precision medicine. John Wiley and Sons Inc. 2016-02-17 2016-03 /pmc/articles/PMC4785018/ /pubmed/26659699 http://dx.doi.org/10.1002/cpt.318 Text en © 2015 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle State of the Art
Chen, B
Butte, AJ
Leveraging big data to transform target selection and drug discovery
title Leveraging big data to transform target selection and drug discovery
title_full Leveraging big data to transform target selection and drug discovery
title_fullStr Leveraging big data to transform target selection and drug discovery
title_full_unstemmed Leveraging big data to transform target selection and drug discovery
title_short Leveraging big data to transform target selection and drug discovery
title_sort leveraging big data to transform target selection and drug discovery
topic State of the Art
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785018/
https://www.ncbi.nlm.nih.gov/pubmed/26659699
http://dx.doi.org/10.1002/cpt.318
work_keys_str_mv AT chenb leveragingbigdatatotransformtargetselectionanddrugdiscovery
AT butteaj leveragingbigdatatotransformtargetselectionanddrugdiscovery